Shares of Spyre Therapeutics Inc. (NASDAQ: SYRE) fell 14% in after-hours trading on Tuesday after the company reported topline results from the rheumatoid arthritis sub-study of its SKYWAY Phase 2 trial evaluating SPY072.
The study, which enrolled 143 participants across three arms, assessed two doses of SPY072 against placebo over 12 weeks. Both low and high doses demonstrated statistically significant improvements on key endpoints, though the magnitude of effect did not meet Spyre’s internal criteria to prioritize monotherapy development for rheumatoid arthritis.
The low-dose cohort showed a change from baseline in DAS28-CRP of -1.9 compared with -1.3 for placebo, alongside an ACR50 response rate of 38% versus 19% for placebo. The high-dose group achieved an ACR20 response rate of 63%, compared with 43% for placebo. Adverse events were reported in 27% of SPY072 recipients versus 36% on placebo, with most events classified as mild or moderate.
Spyre indicated that topline data for SPY072 in psoriatic arthritis and axial spondyloarthritis is expected in the fourth quarter of 2026. Additional topline results for SPY072 in combination with IL-17A/F in hidradenitis suppurativa are anticipated in late 2027 or early 2028.
